€1.3m · Other round · Healthtech · Copenhagen, Denmark
Copenhagen-based 3Sonic has secured €1.3m in convertible financing from BioInnovation Institute to move its surgical imaging technology closer to commercial use. The loan takes BII's cumulative backing of the company to €1.8m and moves 3Sonic from Venture Lab into BII's 18-month Venture House programme.
Photo: Bax Lindhardt, via DTU.
3Sonic is developing a platform that combines three-dimensional ultrasound with artificial intelligence to assess the margins of excised tumour tissue while a patient is still in surgery. The aim is to give surgeons information quickly enough to decide whether more tissue should be removed before the operation ends, instead of waiting for post-operative pathology. The company says it has built a functional prototype and completed clinical proof-of-concept work, but those claims do not establish regulatory approval or commercial readiness.
A 2026 prospective study involving 28 patients undergoing salivary-gland tumour surgery found that a novel 3D ultrasound setup correctly classified specimen margin status in 26 cases, or 93%, when compared with histopathology. The study included contributions from 3Sonic co-founders Fatemeh Makouei and Tobias Todsen. Its authors said larger randomised studies are still needed, particularly because performance differed between benign and malignant tissue.
Funding the step from evidence to workflow
The loan matters because 3Sonic's next challenge is not simply improving image quality. It has to turn a research setup into a repeatable operating-room workflow: acquiring consistent scans, producing trustworthy AI output within minutes, fitting hospital processes and generating evidence strong enough for clinical and regulatory decisions. BII's combination of capital, laboratory access and commercial support is designed for that translation stage.
3Sonic also sits inside AIMICS, a separate five-year collaboration with Rigshospitalet and DTU backed by approximately DKK 30m from Innovation Fund Denmark. DTU says 3Sonic's role is to help scale and disseminate the technology, while the hospital and university contribute clinical and engineering expertise. That project can expand the data and technical base, but the €1.3m BII financing is the company-specific capital intended to strengthen the business and its route to market.
The commercial test will be whether 3Sonic can reproduce promising study results across tumour types and hospitals without disrupting surgical practice. If it can, the value proposition is concrete: faster margin information could reduce repeat procedures and unnecessary additional treatment. Until larger clinical studies and product approvals arrive, that remains a development case rather than an achieved care outcome.
Sources checked:
BioInnovation Institute · 3Sonic · Acta Oto-Laryngologica study · DTU · Tech.eu Funding Explorer
